Skip to content

Author

Linh Tran

We have 2 of 9 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Abstract B053: RAS(ON) inhibition, but not chemotherapy, sensitizes RAS mutant PDAC to immunotherapy via tumor microenvironment remodeling in preclinical models

Pancreatic ductal adenocarcinoma (PDAC) remains largely refractory to immune checkpoint blockade and combining anti-PD-(L)1 therapy with standard-of-care chemotherapy has not improved clinical outcomes over chemotherapy alone. Because oncogenic RAS drives both tumor growth and tumor-intrinsic immune suppression, we h...

L. Grigoryan, Keith Macaraig, Victor Batiste et al. · 0 citations
Aug 2026

Concurrent AXL Inhibition Enhances RAS and ERK Inhibitor Efficacy in KRAS-mutant Pancreatic and Lung Cancer

Combined treatment with the AXL inhibitor bemcentinib together with the RAS(ON) multi-selective tri-complex inhibitor RMC-7977 (RASi) or the ERK-selective inhibitor SCH772984 (ERKi) significantly enhanced growth suppression in human KRAS-mutant pancreatic and lung cancer models.

Yan-Pang Ching, Shruthi Narayanan, Jeffrey A. Klomp et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.